Recommendations are based on the best available evidence, about the use of trastuzumab (Herceptin®) as adjuvant therapy for the treatment of patients with HER2-positive early breast cancer and for the treatment of patients with HER2-positive metastatic breast cancer.
| اسم الملف: | herg-recommendations-trastu...-positive-breast-cancer.pdf |
| حجم الملف: | 291.85 كيلوبايت |
| أنواع السرطان: |
سرطان الثدي
|
| جمهور المنشورات: |
تقارير وخطط مؤسسة السرطان في أستراليا
|
| سنة: | 2007 |
| وضع المستند: |
Greater than 5 years. This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.
|